Taysha Gene Therapies Profit Margin 2020-2024 | TSHA
Current and historical gross margin, operating margin and net profit margin for Taysha Gene Therapies (TSHA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Taysha Gene Therapies net profit margin as of September 30, 2024 is -229.67%.
| Taysha Gene Therapies Annual Profit Margins |
| Taysha Gene Therapies Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.379B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
